Detail akcie Artelo Bioscncs Rg online

Business Summary: Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Artelo Biosciences Inc revenues was not reported. Net loss increased 44% to $8.7M. Higher net loss reflects Net change in fair value of trading mark decrease from $248K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items decreased from -$11.29 to -$13.91.